Clinical Pharmacology of Anti-Epileptic Drugs

  • H. Schneider
  • D. Janz
  • C. Gardner-Thorpe
  • H. Meinardi
  • A. L. Sherwin
Conference proceedings

Table of contents

  1. Front Matter
    Pages I-XII
  2. Pharmacokinetics

    1. Front Matter
      Pages 1-1
    2. E. van der Kleijn, P. J. M. Guelen, C. van Wijk, I. Baars
      Pages 11-33
    3. T. B. Vree, P. T. Henderson, E. van der Kleijn, P. J. M. Guelen
      Pages 34-42
  3. Pharmacology of Anti-Epileptic Drugs

    1. Front Matter
      Pages 55-55
    2. Phenytoin

    3. Ethotoin

    4. Barbiturates

    5. Carbamazepine

    6. Ethosuximide

    7. Dipropylacetate

      1. J. W. A. Meijer, R. Kalff
        Pages 222-228
      2. A. E. H. Sonnen, G. F. Blom, J. W. A. Meijer
        Pages 229-234
    8. Clonazepam

      1. E. F. Hvidberg, O. Sjö
        Pages 242-246
      2. H. J. Knop, E. van der Kleijn, L. C. Edmunds
        Pages 247-260
  4. Various Aspects (Varia)

    1. Front Matter
      Pages 261-261
    2. S. I. Johannessen, R. E. Strandjord
      Pages 262-273
  5. Quality Control and Standardization

    1. Front Matter
      Pages 285-285
    2. J. W. A. Meijer
      Pages 286-292
  6. Methodology of Determination

  7. Dictionary of Anti-Epileptic Drug Synonyms, Chemical Names and Nonproprietary Names

  8. Back Matter
    Pages 362-372

About these proceedings


"He who is faithfully analysing ... epi­ lepsy is doing far more than studying epilepsy" Hughlings Jackson Modifying this well-known statement by Jackson, one could say today: "He who is faithfully analysing anti-epileptic drugs is doing far more than studying anti-epileptic drugs". For these drugs not only serve to prevent epileptic fits and thus advance the treatment of epilepsy, they are also effective in the treatment of cardiac arrhythmias and trigeminal neuralgia. Furthermore, clinical pharmacologists consider anti-epi­ leptic drugs as model drugs in pharmacokinetics and pharmocodynamics, since reliable methods are available for their determination and their effects and side­ effects can be defined. The methods of estimating of drugs in body fluids provide a tool that enables us to throw light on many obscure relationships in pharmaceutical treatment. Now that we can study the pharmacokinetics and interaction of drugs in man, many hypotheses based on clinical experience alone may well be eliminated or corroborated. The grow­ ing body of knowledge will make us more careful about the administration of drugs in combination. Now that we can study how biological parameters interfere with drug action, we may perhaps proceed to the scientific analysis of many clinical observations that suggest the importance of such factors as age, sex, menstrual cycle, pregnancy, fever, diet, stress, sport, climate, and altitude.


drug kinetics pharmacokinetics pharmacology research stress

Editors and affiliations

  • H. Schneider
    • 1
  • D. Janz
    • 2
  • C. Gardner-Thorpe
    • 3
  • H. Meinardi
    • 4
  • A. L. Sherwin
    • 5
  1. 1.Neurophysiol. Abtlg.Ges. f. Epilepsie-Fschg. e. V.Bethel, Maraweg 13Germany
  2. 2.Abteilung für Neurologie im Klinikum CharlottenburgFreien Universität BerlinBerlin 19 (West)Germany
  3. 3.Exeter & Mid-Devon Hospitals, Royal Devon & Exeter Hospitals (Wonford)ExeterEngland
  4. 4.Instituut voor EpilepsiebestrijdingHeemstedeThe Netherlands
  5. 5.Montreal Neurological InstituteMontreal 112Canada

Bibliographic information

  • DOI
  • Copyright Information Springer-Verlag Berlin Heidelberg 1975
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-642-85923-6
  • Online ISBN 978-3-642-85921-2
  • Buy this book on publisher's site